Cover

News

Kernel is advancing precision neuromedicine - Q1 2024 update

February 9, 2024

In the last year we launched Kernel Flow2, shipped our first systems to researchers, published validation work from Flow1, started to build brain-based biomarkers for depression and mild cognitive impairment, completed a number of partnerships to help companies developing products for the brain (not just pharmaceuticals), and refreshed our brand.

Kernel Launches Observational Study Using Flow2 Neuroimaging Technology to Identify Biomarkers of Depression Treatment Response

August 29, 2023

The study utilizes Flow2 to measure patients as they undergo treatment, paving the way to transform how depression is treated with patient-specific biomarkers.

Kernel Launches Cognitive Decline Study Using Flow2 Neuroimaging Technology

August 21, 2023

By leveraging the advanced capabilities of the Flow2 neuroimaging technology, this groundbreaking study aims to detect Mild Cognitive Impairment (MCI) and measure the severity of MCI symptoms by analyzing Flow2 neurophysiological data obtained during a battery of cognitive tasks and resting state measures.

Kernel Introduces Flow2: Revolutionary Advanced Neuroimaging Technology Enabling Precision Neuromedicine

July 31, 2023

With Flow2, researchers and clinicians now have unprecedented access to robust, fMRI-like functional neuroimaging in a quick and user-friendly headset, making precision neuromedicine more accessible than ever before.

Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects

July 20, 2023

The peer-reviewed study, sponsored by Cybin Inc., underscores the ability of Kernel's Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance.

Kernel Flow1 Differentiates Alcohol Doses using Brain Measurements

June 26, 2023

This peer-reviewed study demonstrates the ability of the Kernel Flow1 neuroimaging system to measure dose-dependent brain responses to alcohol.

Better data.
Better brains.